Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Distribution: Plasma Protein Binding01:29

Drug Distribution: Plasma Protein Binding

5.4K
Drugs predominantly attach to plasma proteins, with only a small percentage remaining unbound. The unbound portion can be calculated as one minus the bound fraction. Acidic drugs form large, inactive complexes by reversibly binding to plasma albumin, which prevents them from diffusing across biological barriers. These drug-protein complexes act as reservoirs for the drugs. As the concentration of unbound drugs decreases, these complexes quickly dissociate to release the free drug, maintaining...
5.4K
Factors Affecting Protein-Drug Binding: Protein-Related Factors01:20

Factors Affecting Protein-Drug Binding: Protein-Related Factors

134
Drug binding to proteins is a key aspect of pharmacokinetics and can influence a drug's distribution, absorption, and elimination in the body. Several factors, including the drug's physiochemical properties, protein concentration, disease states, and the number of binding sites on the protein, influence this process.
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
134
Physiological Pharmacokinetic Models: Assumption with Protein Binding01:13

Physiological Pharmacokinetic Models: Assumption with Protein Binding

36
Physiological models with protein binding in pharmacokinetics offer a sophisticated approach to understanding drug disposition. These models consider drug-protein interactions, enabling them to effectively predict drug concentrations in different organs and tissues. This precision aids in accurate drug dosing, providing a significant advantage over conventional models. A key process within these models is equilibration, which ensures that drug concentrations achieve a steady state within the...
36
Factors Affecting Protein-Drug Binding: Patient-Related Factors01:29

Factors Affecting Protein-Drug Binding: Patient-Related Factors

45
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
45
Factors Affecting Protein-Drug Binding: Drug-Related Factors01:18

Factors Affecting Protein-Drug Binding: Drug-Related Factors

87
Drug binding to proteins is a complex phenomenon influenced by various drug-related factors, each playing a significant role in the interaction between drugs and proteins within the body.
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
87
Protein-Drug Binding: Mechanism and Kinetics01:16

Protein-Drug Binding: Mechanism and Kinetics

353
Protein-drug binding refers to the interaction between drugs and proteins within the body. This binding process can occur intracellularly, involving drug interactions with enzymes or receptors within cells, or extracellularly, involving plasma proteins in the blood.
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
353

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

TRPV4: A Promising Therapeutic Target Ion Channel─Discovery of Ultrapotent Selective Antagonists.

Journal of medicinal chemistry·2026
Same author

Linker-Driven Sampling of PROTAC-Induced Ternary Complexes.

Journal of medicinal chemistry·2026
Same author

Misconceptions in Unbound Volume of Distribution and Their Implications for Pharmacokinetic Scaling and Drug Design.

ACS medicinal chemistry letters·2026
Same author

Rethinking Ligand Efficiency: Normalization Pitfalls, Uncertainty, and State-Invariant Metrics.

ACS medicinal chemistry letters·2025
Same author

AI-Augmented R-Group Exploration in Medicinal Chemistry.

Journal of chemical information and modeling·2025
Same author

Structural Basis of Conformational Dynamics in the PROTAC-Induced Protein Degradation.

ChemMedChem·2024

Related Experiment Video

Updated: Jun 13, 2025

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
06:34

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

198

Plasma Protein Binding as an Optimizable Parameter for In Vivo Efficacy.

Hongtao Zhao1

  • 1Medicinal Chemistry, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg SE-43183, Sweden.

Journal of Medicinal Chemistry
|May 28, 2025
PubMed
Summary

Optimizing plasma protein binding is key for drug design. This study shows that strategically adjusting this parameter enhances drug efficacy and safety, improving pharmacokinetic profiles.

More Related Videos

Protein Purification-free Method of Binding Affinity Determination by Microscale Thermophoresis
10:22

Protein Purification-free Method of Binding Affinity Determination by Microscale Thermophoresis

Published on: August 15, 2013

30.5K
A Rapid and Quantitative Fluorimetric Method for Protein-Targeting Small Molecule Drug Screening
08:34

A Rapid and Quantitative Fluorimetric Method for Protein-Targeting Small Molecule Drug Screening

Published on: October 16, 2015

10.0K

Related Experiment Videos

Last Updated: Jun 13, 2025

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
06:34

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

198
Protein Purification-free Method of Binding Affinity Determination by Microscale Thermophoresis
10:22

Protein Purification-free Method of Binding Affinity Determination by Microscale Thermophoresis

Published on: August 15, 2013

30.5K
A Rapid and Quantitative Fluorimetric Method for Protein-Targeting Small Molecule Drug Screening
08:34

A Rapid and Quantitative Fluorimetric Method for Protein-Targeting Small Molecule Drug Screening

Published on: October 16, 2015

10.0K

Area of Science:

  • Pharmacology
  • Drug Discovery
  • Medicinal Chemistry

Background:

  • Plasma protein binding (PPB) is vital for pharmacokinetics, pharmacodynamics, and drug safety.
  • PPB is frequently overlooked as a primary optimization parameter in drug design.
  • Established pharmacokinetic models and extensive compound data are available for analysis.

Purpose of the Study:

  • To challenge the conventional view of PPB in drug design.
  • To investigate the impact of PPB modulation on pharmacokinetic parameters.
  • To elucidate strategies for optimizing PPB to improve drug efficacy and safety.

Main Methods:

  • Revisiting established pharmacokinetic models.
  • Analyzing pharmacokinetic data from 3357 rat compounds.
  • Developing bidirectional optimization strategies for clearance-dependent PPB.

Main Results:

  • Strategies for clearance-dependent optimization of PPB were identified.
  • Modulating PPB was shown to achieve suitable effective half-lives.
  • Strategic PPB modulation significantly enhances drug efficacy and safety.

Conclusions:

  • Plasma protein binding should be considered a critical factor in drug design.
  • Optimizing PPB offers a viable approach to improve drug development outcomes.
  • This study provides a framework for integrating PPB optimization into drug discovery pipelines.